Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2364954 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL18027 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL28060557 | 0.92 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2GPR119SETD7NR1H2 | |
| SCHEMBL29695403 | 0.92 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL282254 | 0.92 | NR1H2 (0.50) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL20051384 | 0.91 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL2443144 | 0.91 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL3551502 | 0.91 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL27671652 | 0.89 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2USP2GPR119SETD7 | |
| SCHEMBL4662077 | 0.87 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2USP2SETD7NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140904-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-0989983-A1 | BENZPYRIDO CYCLOHEPTANE COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1998057960-A1 | BENZPYRIDO CYCLOHEPTANE COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5849746-A | Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | HSD17B10 3161/4885SMN1; SMN2 21/4885USP2 3870/4885 |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | HSD17B10 221/4885SMN1; SMN2 682/4885USP2 2365/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HSD17B10 342/4885SMN1; SMN2 36/4885USP2 913/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | HSD17B10 3072/4885SMN1; SMN2 1682/4885USP2 4319/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HSD17B10 323/4885SMN1; SMN2 37/4885USP2 906/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HSD17B10 687/4885SMN1; SMN2 96/4885USP2 128/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | HSD17B10 1079/4885SMN1; SMN2 1998/4885USP2 635/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HSD17B10 687/4885SMN1; SMN2 96/4885USP2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.